ClinicalTrials.govpublic full text
Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers
subjects with resectable and localized gastric cancer, subjects with resectable esophageal cancer or liver cancer, subjects with resectable liver cancer, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 891741
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.